🔊 Listen to the summary
Artificial intelligence systems have demonstrated the ability to design functional enzyme components, providing new tools to accelerate pharmaceutical synthesis and therapeutic development.
By computationally engineering active biological components, the technology enables the creation of tailored biocatalysts suited for medical applications and complex molecular manufacturing.
The integration of machine learning into enzyme design offers the potential to bypass traditional trial-and-error laboratory processes, streamlining early-stage drug development.
Source: phys.org



